R. Miceli

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Heather A. Wakelee, Amita Patnaik, Branimir I. Šikić et al. · Annals of Oncology · 2009 · 154 citations · Full text

Medicine, Oncology, Pharmacokinetics +14

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Anas Younes, Julie M. Vose, Andrew D. Zelenetz et al. · British Journal of Cancer · 2010 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

Stephen Leong, Roger B. Cohen, Daniel L. Gustafson et al. · Journal of Clinical Oncology · 2009 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Constantijne H. Mom, Jaap Verweij, Corina N.A.M. Oldenhuis et al. · Clinical Cancer Research · 2009 · 104 citations

Medicine, Oncology, Pharmacology +17

Age-dependent effects of lead on [3H]MK-801 binding to the NMDA receptor-gated ionophore: in vitro and in vivo studies

Tomás R. Guilarte, R. Miceli · Neuroscience Letters · 1992 · 98 citations

Life Sciences, Neuroscience, Pharmacology +17